CLINICAL TRIALS PROFILE FOR TAFLUPROST

All Clinical Trials for Tafluprost

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00596791 ↗	Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye Drops	Completed	Santen Oy	Phase 3	2008-01-01	The purpose of this study is to investigate if changes in ocular signs and symptoms occur in patients with ocular hypertension or glaucoma when they switch from latanoprost 0.005% (Xalatan) to preservative free Tafluprost eye drops.
NCT00918346 ↗	Pharmacodynamics of Tafluprost 0.0015% Eye Drops: a Comparison Between the Preserved and Unpreserved Formulation	Completed	Santen Oy	Phase 3	2005-09-01	The objective of this study is to investigate the pharmacodynamics (as expressed in intraocular pressure [IOP]) of two formulations of tafluprost 0.0015% eyedrops (preserved and unpreserved) in patients with open-angle glaucoma or ocular hypertension. The primary aim of this study is to show that IOP reduction between the two formulations is equivalent at the end of the 4 week treatment period.
NCT00966940 ↗	Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension	Completed	Alcon Research	Phase 4	2009-09-01	The purpose of this study is to assess the safety and efficacy of Travoprost 0.004% and Tafluprost 0.0015% in patients with primary open angle glaucoma or ocular hypertension when both medications are administered in the evening.
NCT01026831 ↗	Preservative-Free MK2452 (Tafluprost) for Open-Angle Glaucoma/Ocular Hypertension (MK2452-001)(COMPLETED)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2010-01-06	This study was to compare the safety and efficacy of the preservative-free formulation of 0.0015% MK2452 (tafluprost) and preservative-free 0.5% timolol maleate in patients with open-angle glaucoma and ocular hypertension. This study was to demonstrate that the preservative-free formulation of 0.0015% tafluprost is non-inferior to preservative-free 0.5% timolol maleate.
NCT01087671 ↗	Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost to Preservative Free Tafluprost Eye Drops	Completed	Santen Oy	Phase 3	2010-04-01	The purpose of this study is to investigate if changes in ocular signs and symptoms occur in patients with ocular hypertension or glaucoma when they switch from latanoprost 0.005% (Xalatan) to preservative free Tafluprost eye drops.

Clinical Trial Conditions for Tafluprost

Condition Name

Condition Name for Tafluprost
Intervention	Trials
Ocular Hypertension	18
Glaucoma	11
Open-Angle Glaucoma	7
Primary Open Angle Glaucoma	3

Condition MeSH

Condition MeSH for Tafluprost
Intervention	Trials
Glaucoma	27
Ocular Hypertension	21
Glaucoma, Open-Angle	18
Hypertension	16

Clinical Trial Locations for Tafluprost

Trials by Country

Trials by Country for Tafluprost
Location	Trials
United States	8
Finland	5
Italy	4
Austria	3
Greece	2

Trials by US State

Trials by US State for Tafluprost
Location	Trials
California	2
Pennsylvania	1
Texas	1
Ohio	1
New York	1

Clinical Trial Progress for Tafluprost

Clinical Trial Phase

Clinical Trial Phase for Tafluprost
Clinical Trial Phase	Trials
Phase 4	13
Phase 3	10
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for Tafluprost
Clinical Trial Phase	Trials
Completed	22
Unknown status	4
Recruiting	2

Clinical Trial Sponsors for Tafluprost

Sponsor Name

Sponsor Name for Tafluprost
Sponsor	Trials
Santen Oy	8
Aristotle University Of Thessaloniki	3
Santen Pharmaceutical Co., Ltd.	2

Sponsor Type

Sponsor Type for Tafluprost
Sponsor	Trials
Industry	19
Other	17